03.13.26 -- Advancing Development, Safety, And Optimization Across Complex Therapies

Reconstituted nasal epithelium (RNE) offers a human-relevant model for nasal drug delivery, outperforming frozen mucosa and aligning better with clinical outcomes for opioid formulations.

Highly potent APIs require stringent containment and precise manufacturing controls. Specialized facilities offer end-to-end development solutions and robust cross-contamination protections.

USP 661.1 and 661.2 introduce rigorous, risk-based standards for pharmaceutical plastic packaging, emphasizing material characterization, system suitability, and extractables/leachables testing to ensure safety and compliance.

Integrated development, manufacturing, and quality control under one facility streamlines oral solid dose programs, reducing delays, mitigating risks, and ensuring continuity from early studies through commercial launch.

Advanced particle engineering enhances the performance and life-cycle of therapeutics. Superior bioavailability, higher drug load, and improved stability are enabled for small and large molecules.

Solve the unique challenges of poorly soluble molecules like targeted protein degraders (TPDs), such as PROTACs and molecular glues, seamlessly accelerating your molecule from development to commercialization.

With our services, we support small molecule API synthesis projects from milligram to commercial quantities. We are the partner to address the most difficult challenges, whether the target is difficult to handle, synthesize, or source.

Explore an approach that accelerates your project through key milestones with a technology transfer process that ensures a fast start and process analytical technology that increases efficiency and reduces cost.

Watch to discover the benefits of outsourcing your OSD production and explore real-world examples and best practices to help you streamline your processes and enhance your operational agility.

From gram-scale quantities for early-phase studies to multi-kilogram commercial supply, our facilities and technical teams are equipped to deliver safe, efficient, and compliant solutions.

Accelerate the development of ADCs with capabilities spanning clinical to commercial production, including OEB 5 handling, state-of-the-art fill/finish, and future expanded conjugation services.

Assimilate how a data‑driven discovery model combines DEL screening, computational insights, and medicinal chemistry to accelerate hit‑to‑lead decisions, reduce risk, and enable progression.